ClinicalTrials.gg
CompletedNCT01146678Updated Mar 2, 2011

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

A Phase 1 interventional study of Insulin glargine HOE901 and Lixisenatide AVE0010 in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-03-02.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Planned enrollment
56th of 66
22 · median 73
Started
2010
with 2 others
Phase 1
14 of 66
none open now
Registered
22nd of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 56th largest by planned enrollment, is one of 3 that started in 2010, is one of 14 in phase 1, and was the 22nd registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

  • to assess the relative bioavailability of a single dose of insulin glargine (Lantus) and lixisenatide given subcutaneously as on-site mix versus separate and simultaneous injections of each drug

Secondary Objectives:

  • to compare the activity of a single dose of insulin glargine and lixisenatide given subcutaneously as on-site mix versus separate and simultaneous injections of each drug
  • to assess the safety and tolerability of insulin glargine and lixisenatide given subcutaneously as on-site mix
Read the detailed description

The study period for one patient is one month in average and it can last up to 7 months (+ 2 weeks) with post-study and follow-up visits

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with type 1 diabetes mellitus for more than one year with total insulin dose of \<1.2 U.kg/day, but otherwise healthy with glycohemoglobin () ≤ 9.0%, stable insulin regimen for at least 2 months prior to study, normal finding in medical history and physical examination.

Exclusion criteria

Exclusion criteria:

  • any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type I), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness
  • More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months
  • Frequent severe headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month)
  • Symptomatic hypotension, or asymptomatic postural hypotension defined by a decrease in systolic blood pressure (SBP) equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position
  • Presence or history of a drug allergy to clinically significant allergic disease
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
  • Pregnant or breast feeding women
  • Any medication within 14 days before inclusion, or within 5 times the elimination half-life of that drug, whichever the longest and regular use of any medication other than insulins in the last month before study start with the exception of thyroid hormones, lipid-lowering and antihypertensive drugs, and, if female, with the exception of hormonal or menopausal hormone replacement therapy, any vaccination within the last 28 days.
  • Positive reaction to any of the following tests: surface (HBs Ag) antigen, antihepatitis B core antibodies (anti-HBc Ab) if compound having possible immune activities, anti- virus (anti-HCV2) antibodies, anti- 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)
  • History of unexplained pancreatitis, chronic pancreatitis and/or pancreatectomy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Lantus(insulin glargine)/lixisenatide on-site mix

    Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions

    Drug: Insulin glargine HOE901 · Drug: Lixisenatide AVE0010

  • Active comparator
    lixisenatide + Lantus (insulin glargine)

    Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions

    Drug: Insulin glargine HOE901 · Drug: Lixisenatide AVE0010

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma lixisenatide concentration curve (LIX-AUClast)

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

  2. Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax)

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

Secondary outcomes

  1. Area under the plasma lixisenatide concentration curve (AUC)

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

  2. Time to Cmax (Tmax ) for lixisenatide

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

  3. Area under the body weight standardized glucose infusion rate curve (GIR) within 24 h (GIR-AUC0-24)

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

  4. Time to 50% of the GIR-AUC within 24 h (T50%-GIR AUC0-24)

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

  5. Maximum smoothed body weight standardized glucose infusion rate GIRmax

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

  6. Time to GIRmax (GIR-Tmax)

    Time frame: 1 day (D1 to D2) in the first treatment period and 1 day (D1 to D2) during the second treatment period

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Sep 2010 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2010
First posted
Jun 17, 2010
Start
Jun 2010
Primary completionActual
Sep 2010
CompletionActual
Jan 2011
Last update
Mar 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01146678
Lead sponsor
Sanofi
First posted
Jun 17, 2010
Start date
Jun 2010
Primary completion
Sep 2010
Completion
Jan 2011
Last update
Mar 2, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion